DENVER, Colo., Oct 24, 2023 (www.247marketnews.com)- LianBio (NASDAQ: LIAN) stated, this morning, that Bristol Myers Squibb(NYSE: BMY) obtained LianBio’s exclusive rights, for a total upfront consideration of $350 million, to develop and commercialize mavacamten in Mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand, in conjunction with termination of the exclusive license agreement LianBio previously entered into with MyoKardia, Inc., which is now a wholly owned subsidiary of BMY.
LianBio is trading at $2.20, up $0.81 (+58.27%), on 384.6K premarket shares traded.
Its 52-week range is $1.11 to $2.90. Its next key inflection points are $2.55 and $2.80, and this could hit a new 52-week high today.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
